医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Oxea Announces Price Increase for n-Heptanoic Acid

2014年02月19日 PM04:25
このエントリーをはてなブックマークに追加


 

DALLAS

Oxea will increase list and off-list prices on the following product effective March 1, 2014, or as contracts allow. This price increase is due to recent raw material cost increases.

Product

     

North America
USD/lb

     

Europe
EUR/mt

     

ROW*
USD/mt

n-Heptanoic Acid       0.05       75       100
                 

* ROW = Rest of world

About Oxea

Oxea is a global manufacturer of oxo intermediates and oxo derivatives, such as alcohols, polyols, carboxylic acids, specialty esters, and amines. These products are used for the production of high-quality coatings, lubricants, cosmetics and pharmaceutical products, flavorings and fragrances, printing inks and plastics. In 2012, Oxea generated revenue of about EUR 1.5 billion with its over 1,400 employees worldwide. Oxea is owned by Oman Oil Company S.A.O.C.

For more information about Oxea, visit www.oxea-chemicals.com

About Oman Oil Company

Oman Oil Company S.A.O.C (OOC) is a commercial company wholly owned by the Government established in 1996 to pursue investment opportunities in the wider energy sector both inside and outside Oman. The Company plays an important role in the Sultanate’s efforts to diversify the economy and to promote domestic and foreign investments as well as fostering and building human capital.

CONTACT

Commercial contact:
OXEA GmbH, Otto-Roelen-Str. 3, D-46147
Oberhausen
Oliver Borgmeier, Global Marketing Manager Carboxylic
Acids
Phone: +49 208 693-2332
Fax: +49 208 693-2050
oliver.borgmeier@oxea-chemicals.com
www.oxea-chemicals.com
or
Press
contact:

Birgit Reichel
Phone: +49 208-693-3112
Fax:
+49 208-693-3101
birgit.reichel@oxea-chemicals.com
www.oxea-chemicals.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表